TG Therapeutics (NASDAQ:TGTX) 주식

TG THERAPEUTICS INC

TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Pharmaceutics,Laboratory:,Pipette,Dropping,Yellow,Liquid,Into,Test,Tubes,,Medical

Biotech

Health Care

Technicals

Trading Ideas

TGTX

거래가 다소 저조한 가운데 TG 테라퓨틱스(NASDAQ:TGTX)의 주식은 금요일 오전 1% 이상 상승했으며, 이러한 추세가 계속될 가능성이 높다. 최근 TG 테라퓨틱스가 돌파구를 마련한 것은 강세를 나타낼 수 있다. 이 때문에 우리 거래 전문가 팀이 오늘의 주식으로 선정했다.

오늘의 주식: TG 테라퓨틱스 주식이 저항선을 돌파하며 추가 상승의 가능성이 높아짐

Microstrategy, Marathon Digital Holdings, Coinbase, Cleanspark, And Tesla: 5 Stocks On Investors' Radars Today Amid Bitcoin Buzz

Equities

Mid Cap

News

Movers

ALGM

BILI

MARA

SBSW

지난주 급등한 중형주 8종목 (3월 3일~7일) TG 테라퓨틱스 알레그로 마이크로시스템즈 시바니 스틸워터 하모니 골드 마이닝 빌리빌리 지커 존 윌리 앤 손 마라 홀딩스

빌리빌리·마라홀딩스·지커 등 지난주 급등한 중형주 8종목 (3월 3일~7일)

TG Therapeutics Inc

Earnings

Press Releases

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

General

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Comments

TG Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌